We are very excited to announce our new initiative “Meet the Professional”. This is a new program that aims to bring together HBA members with a professionals established in their field (from the Industry or Academia) in a more casual and informal context.
The meeting has been scheduled for October 5th at 6:30pm and will be focused on “leadership”. Our guest will be Anna Protopapas, President and Chief Executive Officer of Mersana Therapeutics. RSVP Required.
Location: EVOO http://www.evoorestaurant.com/
The discussion will be moderated by an HBA representative (moderator). Participation is restricted to 7-8 HBA members, on first come first serve basis. Please note that each participant will be responsible for their own check. Please contact administrator@hba-usa.org for any questions.
PLEASE REGISTER USING THE EVENTBRITE LINK HERE:
https://www.eventbrite.com/e/meet-the-professional-anna-protopapas-tickets-38094838688?aff=efbevent
Ms. Protopapas joined Mersana in March 2015, bringing a substantial track record of executive leadership and business experience in the biotech industry. Prior to Mersana, Ms.Protopapas was President of Millennium, where she led Takeda Pharmaceutical Co.’s $1.3 billion oncology business. Ms.Protopapas also served as the Executive Vice President of Global Business Development for Takeda Pharmaceuticals where she was responsible for global acquisitions, partnering, licensing and venture investing. In this role, she led Takeda’s $12 billion acquisition of Nycomed, a critical step in the company’s globalization. Ms. Protopapas was a member of Takeda’s executive committee and was elected a corporate officer in 2011. Earlier, Ms. Protopapas was an executive officer at Millennium Pharmaceuticals and served in various senior leadership positions, playing an integral role in the company’s transformation from a genomics start-up to a fully integrated oncology leader. She was instrumental in the sale of Millennium to Takeda for $8.8 billion. She earned her bachelor’s degree in science and engineering from Princeton University, a master’s in chemical engineering practice from the Massachusetts Institute of Technology and an M.B.A. from Stanford Graduate School of Business.
